Physician
Balm of Gilead Medical Office, PC
Balm of Gilead Medical Office, PC was paid $5.95M by Medicaid between Jan 2018 and Dec 2024, across 47 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 68% of everything it billed.
33Billing provider infoBALM OF GILEAD MEDICAL OFFICE, PC
BRONX, NY 10470
BRONX, NY 10470
33aNPI1720104474assigned 03/22/2007
33bProvider typeInternal Medicine Physician
28Total paid$5.95M
24GClaims113,067
24DCodes billed47
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Internal Medicine Physician providers in New York
Rank by total paid#40 of 6,049
Median peer was paid$11K
This provider vs. median526×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 29,271 | $922K | |
| 2019 | 14,459 | $754K | |
| 2020 | 16,116 | $843K | |
| 2021 | 17,278 | $1.07M | |
| 2022 | 13,760 | $898K | |
| 2023 | 12,320 | $802K | |
| 2024incomplete | 9,863 | $656K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 68% | 59,575 | 55,593 | $4.03M |
| 62323 | 17% | 4,882 | 4,868 | $1.03M | |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 2.8% | 1,737 | 1,683 | $169K |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 2.1% | 1,404 | 1,403 | $127K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 1.5% | 1,535 | 1,510 | $88K |
| 20611 | 1.4% | 968 | 950 | $81K | |
| 99401 | 1.1% | 2,418 | 2,348 | $66K | |
| 72275 | <1% | 596 | 590 | $42K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 234 | 232 | $37K |
| 80321 | <1% | 973 | 942 | $28K | |
| 80372 | <1% | 972 | 941 | $28K | |
| 80354 | <1% | 973 | 942 | $28K |
35 more codes
| 80373 | <1% | 973 | $28K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 232 | $26K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 211 | $21K |
| 99404 | <1% | 338 | $13K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 944 | $11K |
| 83992 | <1% | 973 | $10K | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 844 | $8K |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 5,197 | $7K |
| 80358 | <1% | 973 | $5K | |
| 80359 | <1% | 973 | $5K | |
| 80349 | <1% | 973 | $5K | |
| 80353 | <1% | 973 | $5K | |
| 80324 | <1% | 973 | $5K | |
| 80356 | <1% | 973 | $5K | |
| 80361 | <1% | 973 | $5K | |
| 80346 | <1% | 973 | $5K | |
| 80365 | <1% | 972 | $5K | |
| 80348 | <1% | 973 | $5K | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 5,087 | $4K |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 25 | $3K |
| 62321 | <1% | 12 | $2K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 54 | $2K |
| 20610 | <1% | 28 | $2K | |
| 76942 | <1% | 12 | $1K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 794 | $1K |
| 96125 | <1% | 30 | $579.87 | |
| G0444 | Annual depression screening, 5 to 15 minutes | <1% | 233 | $176.13 |
| 99070 | <1% | 846 | $105.00 | |
| 99406 | <1% | 12 | $78.75 | |
| 1126F | <1% | 137 | $63.33 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 388 | $3.58 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 25 | $3.07 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 6,051 | $1.97 |
| 99000 | 0% | 2,448 | $0.00 | |
| 99072 | 0% | 1,177 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialEMILI, GREGORY (ASSOCIATE PROGRAM DIRECTOR)